Therapy of human T-cell acute lymphoblastic leukaemia in severe combined immunodeficient mice with two different anti-CD7-saporin immunotoxins containing hindered or non-hindered disulphide cross-linkersFLAVELL, D. J; BOEHM, D. A; OKAYAMA, K et al.International journal of cancer. 1994, Vol 58, Num 3, pp 407-414, issn 0020-7136Article

Preclinical studies with the anti-CD19-saporin immunotoxin BU12-SAPORIN for the treatment of human-B-cell tumoursFLAVELL, D. J; FLAVELL, S. U; BOEHM, D. A et al.British journal of cancer. 1995, Vol 72, Num 6, pp 1373-1379, issn 0007-0920Article

Comparison of the potency and therapeutic efficacy of the anti-CD7 immunotoxin HB2-saporin constructed with one or two saporin moieties per immunotoxin moleculeFLAVELL, D. J; BOEHM, D. A; NOSS, A et al.British journal of cancer. 1997, Vol 75, Num 7, pp 1035-1043, issn 0007-0920Article

Therapy of human T-cell acute lymphoblastic leukaemia with a combination of anti-CD7 and anti-CD38-SAPORIN immunotoxins is significantly better than therapy with each individual immunotoxinFLAVELL, D. J; BOEHM, D. A; NOSS, A et al.British journal of cancer. 2001, Vol 84, Num 4, pp 571-578, issn 0007-0920Article

Therapy of human B-cell lymphoma bearing SCID mice is more effective with anti-CD19- and anti-CD38-SAPORIN immunotoxins used in combination than with either immunotoxin used aloneFLAVELL, D. J; BOEHM, D. A; EMERY, L et al.International journal of cancer. 1995, Vol 62, Num 3, pp 337-344, issn 0020-7136Article